GABAergic Signalling
Cross-source consensus on GABAergic Signalling from 1 sources and 5 claims.
1 sources · 5 claims
How it works
Benefits
Highlighted claims
- In typical mature neural circuits, GABA_A receptor signalling is mainly inhibitory. — Efficacy of bumetanide for cognitive improvement in children and adolescents with Down syndrome: study protocol of a randomised, double-blind, placebo-controlled trial
- Upregulated NKCC1 raises intracellular chloride, disrupting the excitation/inhibition balance required for synaptic plasticity, learning, and memory. — Efficacy of bumetanide for cognitive improvement in children and adolescents with Down syndrome: study protocol of a randomised, double-blind, placebo-controlled trial
- Preclinical studies in DS mouse models found bumetanide restored GABAergic signals, synaptic plasticity, hippocampus-dependent memory, and sleep quality. — Efficacy of bumetanide for cognitive improvement in children and adolescents with Down syndrome: study protocol of a randomised, double-blind, placebo-controlled trial
- Pharmacological reduction of GABA_A-mediated signalling has rescued long-term potentiation and cognitive deficits in DS mouse models, supporting the GABAergic system as a therapeutic target. — Efficacy of bumetanide for cognitive improvement in children and adolescents with Down syndrome: study protocol of a randomised, double-blind, placebo-controlled trial
- In Down syndrome, evidence from mouse models, postmortem brains, and iPSC-derived neurons suggests GABA_A receptor-mediated signalling may become depolarising and potentially excitatory. — Efficacy of bumetanide for cognitive improvement in children and adolescents with Down syndrome: study protocol of a randomised, double-blind, placebo-controlled trial